304 related articles for article (PubMed ID: 25288110)
1. Golimumab in uveitis previously treated with other anti-TNF-alpha drugs: a retrospective study of three cases from a single centre and literature review.
Calvo-Río V; de la Hera D; Blanco R; Beltrán-Catalán E; Loricera J; Cañal J; Ventosa J; Cifrián JM; Ortiz-Sanjuán F; Rueda-Gotor J; González-Vela MC; González-López M; González-Gay MA
Clin Exp Rheumatol; 2014; 32(6):864-8. PubMed ID: 25288110
[TBL] [Abstract][Full Text] [Related]
2. Tocilizumab in uveitis refractory to other biologic drugs: a study of 3 cases and a literature review.
Calvo-Río V; de la Hera D; Beltrán-Catalán E; Blanco R; Hernandez M; Martínez-Costa L; Loricera J; Cañal J; Ventosa J; Ortiz-Sanjuán F; Pina T; González-Vela MC; Rodríguez-Cundín P; González-Gay MA
Clin Exp Rheumatol; 2014; 32(4 Suppl 84):S54-7. PubMed ID: 25005576
[TBL] [Abstract][Full Text] [Related]
3. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
[TBL] [Abstract][Full Text] [Related]
4. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults.
Borrás-Blasco J; Casterá DE; Cortes X; Abad FJ; Rosique-Robles JD; Mallench LG
Int J Clin Pharmacol Ther; 2015 May; 53(5):377-90. PubMed ID: 25345430
[TBL] [Abstract][Full Text] [Related]
6. Golimumab in refractory uveitis related to spondyloarthritis. Multicenter study of 15 patients.
Calvo-Río V; Blanco R; Santos-Gómez M; Rubio-Romero E; Cordero-Coma M; Gallego-Flores A; Veroz R; Torre I; Hernández FF; Atanes A; Loricera J; González-Vela MC; Palmou N; Hernández JL; González-Gay MA
Semin Arthritis Rheum; 2016 Aug; 46(1):95-101. PubMed ID: 27060872
[TBL] [Abstract][Full Text] [Related]
7. Behçet disease-associated uveitis successfully treated with golimumab.
Mesquida M; Victoria Hernández M; Llorenç V; Pelegrín L; Espinosa G; Dick AD; Adán A
Ocul Immunol Inflamm; 2013 Apr; 21(2):160-2. PubMed ID: 23252659
[TBL] [Abstract][Full Text] [Related]
8. Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review.
Palmou-Fontana N; Calvo-Río V; Martín-Varillas JL; Fernández-Díaz C; Mesquida M; Adán A; Hernández MV; Cordero-Coma M; Maiz Alonso O; Díaz-Valle D; Fernández-Cid C; Ruiz-Moreno O; Hernández JL; González-Gay MA; Blanco R
Clin Exp Rheumatol; 2018; 36(4):652-657. PubMed ID: 29303704
[TBL] [Abstract][Full Text] [Related]
9. Recalcitrant psoriatic uveitis and anti-tumor necrosis factor-α monoclonal antibodies: experience from a psoriasis referral center.
Fotiadou C; Lazaridou E; Kemanetzi C; Kyrmanidou E; Ioannides D
Int J Dermatol; 2015 Sep; 54(9):1105-8. PubMed ID: 25557117
[TBL] [Abstract][Full Text] [Related]
10. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
[TBL] [Abstract][Full Text] [Related]
11. Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab.
Lanz S; Seidel G; Skrabl-Baumgartner A
Pediatr Rheumatol Online J; 2021 Aug; 19(1):132. PubMed ID: 34419092
[TBL] [Abstract][Full Text] [Related]
12. Anti-tumor necrosis factor-α therapy in uveitis.
Cordero-Coma M; Sobrin L
Surv Ophthalmol; 2015; 60(6):575-89. PubMed ID: 26164735
[TBL] [Abstract][Full Text] [Related]
13. Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience.
Cordero-Coma M; Calvo-Río V; Adán A; Blanco R; Álvarez-Castro C; Mesquida M; Calleja S; González-Gay MA; Ruíz de Morales JG
Mediators Inflamm; 2014; 2014():717598. PubMed ID: 24976689
[TBL] [Abstract][Full Text] [Related]
14. Tumour necrosis factor alpha inhibitors in the treatment of childhood uveitis.
Saurenmann RK; Levin AV; Rose JB; Parker S; Rabinovitch T; Tyrrell PN; Feldman BM; Laxer RM; Schneider R; Silverman ED
Rheumatology (Oxford); 2006 Aug; 45(8):982-9. PubMed ID: 16461435
[TBL] [Abstract][Full Text] [Related]
15. Anti-TNF-alpha therapy in patients with chronic non-infectious uveitis: the experience of Jules Gonin Eye Hospital.
Petropoulos IK; Vaudaux JD; Guex-Crosier Y
Klin Monbl Augenheilkd; 2008 May; 225(5):457-61. PubMed ID: 18454398
[TBL] [Abstract][Full Text] [Related]
16. TNF inhibition for ophthalmic indications: current status and outlook.
Rifkin LM; Birnbaum AD; Goldstein DA
BioDrugs; 2013 Aug; 27(4):347-57. PubMed ID: 23568177
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment with golimumab for severe uveitis.
Miserocchi E; Modorati G; Pontikaki I; Meroni PL; Gerloni V
Ocul Immunol Inflamm; 2014 Apr; 22(2):90-5. PubMed ID: 24143896
[TBL] [Abstract][Full Text] [Related]
18. Adalimumab therapy for refractory uveitis: results of a multicentre, open-label, prospective trial.
Suhler EB; Lowder CY; Goldstein DA; Giles T; Lauer AK; Kurz PA; Pasadhika S; Lee ST; de Saint Sardos A; Butler NJ; Tessler HH; Smith JR; Rosenbaum JT
Br J Ophthalmol; 2013 Apr; 97(4):481-6. PubMed ID: 23376607
[TBL] [Abstract][Full Text] [Related]
19. Use of Anti-Tumour Necrosis Factor-Alpha Agents in the Management of HLA-B-27-Associated Uveitis: The First Case Series from India.
Lakra R; Shah A; Kaushik V; Biswas J; Dutta Majumder P
Ocul Immunol Inflamm; 2021 Feb; 29(2):232-236. PubMed ID: 32058826
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of intravitreal anti-tumour necrosis factor drugs in adults with non-infectious uveitis - a systematic review.
Leal I; Rodrigues FB; Sousa DC; Romão VC; Duarte GS; Carreño E; Dick AD; Marques-Neves C; Costa J; Fonseca JE
Acta Ophthalmol; 2018 Sep; 96(6):e665-e675. PubMed ID: 29577629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
